Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzolamide and Brimonidine Interaction Study
NCT02967614Phase 1Completed
- Sponsor
- Kukje Pharm
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dorzolamide and brimonidine tartrate + sodium hyaluronate in Glaucoma and ocular hypertension, sponsored by Kukje Pharm. Primary endpoint: Plasma concentration of Brimonidine. Started Dec 2016; status: completed.
02
Drugs
dorzolamidebrimonidine tartrate + sodium hyaluronate
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT02967614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967614.